Comparison study of the effect of erlotinib as a tyrosine kinase inhibitor on electrolyte levels in type2 diabetic and diabetic nephropathy

Abstract EN

Diabetes mellitus can be defined as a metabolic disorder disease.

Complication of diabetes are due to diabetic nephropathy.

This study was done in vitro to study the effect of different concentrations of erlotinib inhibitor (tyrosine kinase inhibitor) on electrolyte levels (Mg⁺², Ca⁺², Na⁺) in sera of Iraqi patients with newly diagnosis type2 diabetes and diabetic nephropathy in addition to find the best percentage inhibition for utilizing different concentrations from erlotinib (6.97x10⁻⁷, 9.30x10⁻⁷ ,1.16x10⁻⁶,1.39x10⁻⁶ ,1.62x10⁻⁵) molar on electrolyte levels.

This study was conducted in The National Diabetes Center, Al- Mustansiriya University - Baghdad and included 150 patients divided into50 patients type 2 diabetic as group (G2), 50patients diabetic nephropathy as group(G3) and also 50 healthy as control group(G1).

The period time for aggregation the blood sampling was from July to October 2017.

All patients were within (18 to 60) year's age.

Erlotinib (Tyrosine kinase inhibitor) affected on serum Mg ⁺²levels in human as a mild effect and a slight effect on serum Na⁺ and Ca⁺².The best inhibition of erlotinib in concentration (1.62x10⁻5) M for both serum Na⁺ and Ca⁺² in newly diagnosis diabetes type 2 and diabetic nephropathy.

Serum Mg ⁺²levels showed best inhibition in concentration (9.30x10⁻7) M.